{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:09:10Z","timestamp":1790964550615,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Empagliflozin (EMPA) therapy has led to improvements in patients with non-alcoholic fatty liver disease (NAFLD). Sestrin2 is a stress-inducible protein that controls the AMPK-mTOR pathway and inhibits oxidative damage in cells. This study investigated the functional implications of EMPA on the multifactorial pathogenesis of NAFLD and potential underlying molecular mechanisms of pathogenesis. An <jats:italic>in vitro<\/jats:italic> model of NAFLD was established by treating HepG2 cells with palmitic acid (PA); an <jats:italic>in vivo<\/jats:italic> model of NAFLD was generated by feeding C57BL\/6 mice a high-fat diet. Investigations of morphology and lipid deposition in liver tissue were performed. Expression patterns of Sestrin2 and genes related to lipogenesis and inflammation were assessed by reverse transcription polymerase chain reaction. Protein levels of Sestrin2 and AMPK\/mTOR pathway components were detected by Western blotting. NAFLD liver tissues and PA-stimulated HepG2 cells exhibited excessive lipid production and triglyceride secretion, along with upregulation of Sestrin2 and increased expression of lipogenesis-related genes. EMPA treatment reversed liver damage by upregulating Sestrin2 and activating the AMPK-mTOR pathway. Knockdown of Sestrin2 effectively increased lipogenesis and enhanced the mRNA expression levels of lipogenic and pro-inflammatory genes in PA-stimulated HepG2 cells; EMPA treatment did not affect these changes. Furthermore, Sestrin2 knockdown inhibited AMPK-mTOR signaling pathway activity. The upregulation of Sestrin2 after treatment with EMPA protects against lipid deposition-related metabolic disorders; it also inhibits lipogenesis and inflammation through activation of the AMPK-mTOR signaling pathway. These results suggest that Sestrin2 can be targeted by EMPA therapy to alleviate lipogenesis and inflammation in obesity-related NAFLD.<\/jats:p>","DOI":"10.3389\/fphar.2022.944886","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T04:41:31Z","timestamp":1662352891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Empagliflozin activates Sestrin2-mediated AMPK\/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuting","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenggguang","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxia","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00408-019-00205-8","article-title":"Investigation of urinary Sestrin2 in patients with obstructive sleep apnea","volume":"197","author":"Bai","year":"2019","journal-title":"Lung"},{"key":"B2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2337\/db12-0139","article-title":"Sterol regulatory element-binding protein-1c mediates increase of postprandial stearic acid, a potential target for improving insulin resistance, in hyperlipidemia","volume":"62","author":"Chu","year":"2013","journal-title":"Diabetes"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e3413","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials","volume":"37","author":"Coelho","year":"2020","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","article-title":"AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance","volume":"66","author":"Garcia","year":"2017","journal-title":"Mol. Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"751020","DOI":"10.3389\/fendo.2021.751020","article-title":"Sestrin2 as a potential target for regulating metabolic-related diseases","volume":"12","author":"Gong","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbrc.2020.03.032","article-title":"Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2\/HO-1 pathway","volume":"525","author":"Han","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","article-title":"SGLT2 inhibitors in liver patients","volume":"18","author":"Hsiang","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.bbadis.2017.02.018","article-title":"Knockdown of sestrin2 increases pro-inflammatory reactions and ER stress in the endothelium via an AMPK dependent mechanism","volume":"1863","author":"Hwang","year":"2017","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"115036","DOI":"10.1016\/j.taap.2020.115036","article-title":"Luteolin prevents liver from tunicamycin-induced endoplasmic reticulum stress via nuclear factor erythroid 2-related factor 2-dependent sestrin 2 induction","volume":"399","author":"Jegal","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"470\u2013479","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"Jeon","year":"2020","journal-title":"J. Lipid Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2017.05.026","article-title":"Carbon monoxide protects against hepatic steatosis in mice by inducing sestrin-2 via the PERK-eIF2\u03b1-ATF4 pathway","volume":"110","author":"Kim","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/ijms22031200","article-title":"The protective role of Sestrin2 in atherosclerotic and cardiac diseases","volume":"22","author":"Kishimoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"29\u201341","DOI":"10.1016\/j.bcp.2016.01.011","article-title":"Activation of the MAPK\/Akt\/Nrf2-Egr1\/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death","volume":"104","author":"Koyani","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-med-042017-094221","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type 2 diabetes","volume":"70","author":"Kramer","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"n1091","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: A clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1440-1746.2009.06086.x","article-title":"Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis","volume":"25","author":"Liu","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cca.2010.09.025","article-title":"Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome","volume":"412","author":"Lucero","year":"2011","journal-title":"Clin. Chim. Acta."},{"key":"B45","doi-asserted-by":"publisher","first-page":"393\u2013416","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.2174\/13816128113199990344","article-title":"Pathophysiology of NASH: Perspectives for a targeted treatment","volume":"19","author":"Marra","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1074\/jbc.M114.622571","article-title":"Reciprocal regulation of AMP-activated protein kinase and phospholipase D","volume":"290","author":"Mukhopadhyay","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease","volume":"15","author":"Neuschwander-Tetri","year":"2017","journal-title":"BMC Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2010.02.029","article-title":"Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice","volume":"53","author":"Obara","year":"2010","journal-title":"J. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1038\/ncomms5233","article-title":"Hepatoprotective role of Sestrin2 against chronic ER stress","volume":"5","author":"Park","year":"2014","journal-title":"Nat. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.yjmcc.2018.01.005","article-title":"Sestrin2 prevents age-related intolerance to post myocardial infarction via AMPK\/PGC-1\u03b1 pathway","volume":"115","author":"Quan","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11892-015-0607-4","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: Common pathophysiologic mechanisms","volume":"15","author":"Saponaro","year":"2015","journal-title":"Curr. Diab. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"E1907","DOI":"10.3390\/ijms21061907","article-title":"Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis","volume":"21","author":"Sumida","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.14336\/AD.2019.0320","article-title":"The emerging role of Sestrin2 in cell metabolism, and cardiovascular and age-related diseases","volume":"11","author":"Sun","year":"2020","journal-title":"Aging Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.21037\/hbsn.2018.01.01","article-title":"Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario","volume":"7","author":"Vigan\u00f2","year":"2018","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/21623945.2017.1413516","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"key":"B40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2337\/db20-0146","article-title":"A high-fat diet attenuates AMPK \u03b11 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo","volume":"70","author":"Yan","year":"2021","journal-title":"Diabetes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/ars.2018.7559","article-title":"Inhibitory effect of Sestrin2 on hepatic stellate cell activation and liver fibrosis via blocking transforming growth factor-\u03b2 signaling","volume":"31","author":"Yang","year":"2019","journal-title":"Antioxidants Redox Signal."},{"key":"B42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4254\/wjh.v5.i10.550","article-title":"Lipotoxicity in the liver","volume":"5","author":"Z\u00e1mb\u00f3","year":"2013","journal-title":"World J. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.944886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T04:41:35Z","timestamp":1662352895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.944886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":47,"alternative-id":["10.3389\/fphar.2022.944886"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.944886","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"article-number":"944886"}}